Source comparison
BPC-157 Research Endocrine Considerations: [Peptide Type] Comparison
BPC-157 Growth hormone receptor upregulation, thyroid deiodinase modulation, HPA axis dampening Increases hepatic GHR density, enhances T4-to-T3 conversion via D1 enzyme, reduces stress-induced CRH secretion +34% GHR expression, +22% IGF-1, +18% D1 activity, −
This comparison does not assign a generated winner or score.
- BPC-157
- Growth hormone receptor upregulation, thyroid deiodinase modulation, HPA axis dampening
- Increases hepatic GHR density, enhances T4-to-T3 conversion via D1 enzyme, reduces stress-induced CRH secretion
- +34% GHR expression, +22% IGF-1, +18% D1 activity, −29% stress corticosterone
- Broadest endocrine footprint among gastric peptides. Systemic metabolic effects require monitoring in all protocols
- Thymosin Beta-4 (TB-500)
- Minimal direct endocrine interaction
- Primarily actin-sequestering. Promotes cell migration and angiogenesis without significant hormone receptor modulation
- No documented changes in GH, thyroid, or cortisol pathways at standard research doses
- Cleaner mechanistic profile for isolated tissue studies. Fewer confounding metabolic variables
- GHK-Cu
- Indirect IGF-1 modulation through copper-dependent enzyme activation
- Copper peptide activates lysyl oxidase and superoxide dismutase. Downstream effects on collagen cross-linking and oxidative stress
- Modest IGF-1 increases (8–12% in wound models). No documented thyroid or HPA axis effects
- Minimal systemic endocrine impact. Suitable for localized tissue repair studies without metabolic confounders